Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Allogene Therapeutics, Inc. (ALLO)
USD1.83
-0.03 (-1.35%)
US NASDAQ Healthcare Biotechnology
Address
210 East Grand Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
David D. Chang
Website
allogene.com
IPO
2018-10-11
CIK 1737287 ISIN US0197701065
Description
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.83
-0.03 (-1.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.46
Float Shares
162.26M
Free Float %
66.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.30% | +1.75% | -23.86% | +29.44% | +94.17% | +70.07% | +106.19% | -65.43% | -91.35% | -90.68% | -90.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (30 ratings, all time)
Buy
Price Targets & DCF
Current price
1.83
Low
3.85
+111.0%
Consensus
6.43
+252.3%
Median
6.43
+252.1%
High
9.00
+393.2%
Ratings Trend (MoM)
87% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | -1 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
6.43
+252.3%
|
| Last Quarter | 2 |
6.43
+252.3%
|
| Last Year | 2 |
6.43
+252.3%
|
| All Time | 12 |
25.24
+1,283.0%
|
Quality scores
Altman Z-Score
-5.11
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+34.1% ★ Q1'26: +35.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-176.3% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.3% Q1'26: +11.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.39× Q1'26: -0.39× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 10 Rev. Ana. 12 EPS Ana. |
Dec 2029 5 Rev. Ana. 10 EPS Ana. |
Dec 2030 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 2.93M (-100.0%)
|
114.09M
est: 38.32M (+197.8%)
|
156.0K
est: 178.0K (-12.3%)
|
95.0K
est: 65.0K (+46.2%)
|
22.0K
est: 23.9K (-7.9%)
|
—
est: 1.7K (-100.0%)
|
12.9K
12.9K – 12.9K
+671.3% YoY
|
19.73M
19.73M – 19.73M
+153,341.1% YoY
|
101.44M
101.44M – 101.44M
+414.2% YoY
|
306.86M
306.86M – 306.86M
+202.5% YoY
|
590.63M
590.63M – 590.63M
+92.5% YoY
|
| EBITDA |
-238.68M
est: -257.08M (+7.2%)
|
-169.74M
est: -264.43M (+35.8%)
|
-321.24M
est: -287.41M (-11.8%)
|
-313.07M
est: -39.0K (-802,633.3%)
|
-243.33M
est: -14.3K (-1,698,517.8%)
|
-194.57M
est: -1.0K (-19,457,300.0%)
|
-7.7K
-7.7K – -7.7K
-671.4% YoY
|
-11.84M
-11.84M – -11.84M
-153,345.1% YoY
|
-60.86M
-60.86M – -60.86M
-414.2% YoY
|
-184.12M
-184.12M – -184.12M
-202.5% YoY
|
-354.38M
-354.38M – -354.38M
-92.5% YoY
|
| EBIT |
-250.22M
est: -273.60M (+8.5%)
|
-180.19M
est: -274.70M (+34.4%)
|
-335.54M
est: -298.90M (-12.3%)
|
-327.27M
est: -39.0K (-839,041.0%)
|
-256.97M
est: -14.3K (-1,793,729.0%)
|
-206.93M
est: -1.0K (-20,693,200.0%)
|
-7.7K
-7.7K – -7.7K
-671.4% YoY
|
-11.84M
-11.84M – -11.84M
-153,345.1% YoY
|
-60.86M
-60.86M – -60.86M
-414.2% YoY
|
-184.12M
-184.12M – -184.12M
-202.5% YoY
|
-354.38M
-354.38M – -354.38M
-92.5% YoY
|
| Net Income |
-250.22M
est: -264.99M (+5.6%)
|
-182.05M
est: -275.94M (+34.0%)
|
-340.41M
est: -300.14M (-13.4%)
|
-327.27M
est: -354.54M (+7.7%)
|
-257.59M
est: -298.31M (+13.7%)
|
-190.89M
est: -190.89M (+0.0%)
|
-190.46M
-198.39M – -114.98M
+0.2% YoY
|
-207.79M
-222.12M – -96.88M
-9.1% YoY
|
-195.11M
-216.36M – -56.82M
+6.1% YoY
|
-7.79M
-7.79M – -7.79M
+96.0% YoY
|
174.29M
174.29M – 174.29M
+2,337.2% YoY
|
| SGA |
65.26M
est: 2.48B (-97.4%)
|
74.11M
est: 32.40B (-99.8%)
|
79.31M
est: 150.49M (-47.3%)
|
71.67M
est: 54.97M (+30.4%)
|
65.21M
est: 20.19M (+223.0%)
|
56.78M
est: 1.41M (+3,927.8%)
|
10.87M
10.87M – 10.87M
+671.3% YoY
|
16.68B
16.68B – 16.68B
+153,341.1% YoY
|
85.78B
85.78B – 85.78B
+414.2% YoY
|
259.50B
259.50B – 259.50B
+202.5% YoY
|
499.47B
499.47B – 499.47B
+92.5% YoY
|
| EPS |
-2.08
est: -2.12 (+2.0%)
|
-1.34
est: -1.96 (+31.8%)
|
-2.38
est: -2.37 (-0.5%)
|
-2.09
est: -1.61 (-30.1%)
|
-1.32
est: -1.33 (+0.9%)
|
-0.87
est: -0.93 (+6.1%)
|
-0.75
-0.90 – -0.52
+19.5% YoY
|
-0.74
-1.01 – -0.44
+0.9% YoY
|
-0.66
-0.98 – -0.26
+10.2% YoY
|
-0.04
-0.04 – -0.04
+94.7% YoY
|
0.79
0.79 – 0.79
+2,337.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-16 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-109.23M
OE per share TTM
-0.49
Owner's Yield
-19.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
914.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
59
Total invested
37.62M
Insider transactions (90d)
1
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PF Equity Holdings 2 B.V. (“Holdings”) | 22.03M | 15.50% | — | 22.03M | — | 10.00 | CO | NETHERLANDS | 2021-09-17 | ↗ |
| 2 | Pfizer Inc. (“Pfizer”) | 22.03M | 15.50% | — | 22.03M | — | 10.00 | CO | DELAWARE | 2021-09-17 | ↗ |
| 3 | David Bonderman | 19.72M | 14.20% | — | 19.72M | — | — | IN | United States of America | 2020-07-10 | ↗ |
| 4 | James G. Coulter | 19.72M | 14.20% | — | 19.72M | — | — | IN | United States of America | 2020-07-10 | ↗ |
| 5 | TPG Group Holdings (SBS) Advisors, Inc. | 19.72M | 14.20% | — | — | — | — | CO | Delaware | 2020-07-10 | ↗ |
| 6 | Group Holdings (SBS) Advisors, Inc. | 18.72M | 13.40% | — | 18.72M | — | — | CO | Delaware | 2020-08-10 | ↗ |
| 7 | Bonderman | 18.72M | 13.20% | — | 18.72M | — | — | IN | States of America | 2022-01-18 | ↗ |
| 8 | G. Coulter | 18.72M | 13.20% | — | 18.72M | — | — | IN | States of America | 2022-01-18 | ↗ |
| 9 | GP A, LLC | 18.72M | 13.20% | — | 18.72M | — | — | OO | Delaware | 2022-01-18 | ↗ |
| 10 | Winkelried | 18.72M | 13.20% | — | 18.72M | — | — | IN | States of America | 2022-01-18 | ↗ |
| 11 | STATE STREET CORPORATION | 9.17M | 6.36% | — | — | — | — | HC | — | 2023-02-03 | ↗ |
| 12 | (1) BlackRock, Inc. | 8.89M | 6.20% | 8.53M | — | 8.89M | — | HC | Delaware | 2023-02-03 | ↗ |
| 13 | Page 2 of 5 Pages | 8.59M | 7.00% | — | 13.00 | — | — | OO | California | 2020-02-13 | ↗ |
| 14 | David Chang, M.D., Ph.D. | 8.43M | 5.70% | 5.51M | 2.91M | 5.51M | 2.91M | IN | — | 2023-02-13 | ↗ |
| 15 | SSGA FUNDS MANAGEMENT, INC. | 7.53M | 5.22% | — | — | — | 7.53M | IA | — | 2023-02-03 | ↗ |
| 16 | of 5 Pages | 7.34M | 5.20% | — | 13.00 | 7.34M | — | OO | California | 2021-02-12 | ↗ |
| 17 | The Vanguard Group - 23-1945930 | 7.27M | 5.04% | — | — | 7.13M | 134.9K | IA | Pennsylvania | 2023-02-09 | ↗ |
| 18 | Arie Belldegrun, M.D. | 7.20M | 5.00% | 655.0K | 6.55M | 655.0K | 6.55M | IN | — | 2022-02-14 | ↗ |
| 19 | Seaview Trust | 7.04M | 4.94% | 7.04M | — | 7.04M | — | OO | California | 2022-02-14 | ↗ |
| 20 | Capital Research Global Investors ** | 6.54M | 5.30% | 6.54M | — | — | — | IA | — | 2020-02-14 | ↗ |
| 21 | Bellco Legacy IV, LLC | 4.71M | 3.30% | — | 4.71M | — | 4.71M | OO | — | 2022-02-14 | ↗ |
| 22 | Vida Ventures LLC | 1.80M | 1.30% | — | 1.80M | — | 1.80M | OO | — | 2022-02-14 | ↗ |
| 23 | Chang 2006 Family Trust | 1.20M | 0.80% | — | 1.20M | — | 1.20M | OO | — | 2023-02-13 | ↗ |
| 24 | Gilead Sciences, Inc. | 1.16M | 0.80% | 1.16M | — | 1.16M | — | CO | — | 2022-02-10 | ↗ |
| 25 | JEC 2019 Trust | 856.0K | 0.60% | — | 856.0K | — | 856.0K | OO | — | 2023-02-13 | ↗ |
| 26 | RTC 2019 Trust | 856.0K | 0.60% | — | 856.0K | — | 856.0K | OO | — | 2023-02-13 | ↗ |
| 27 | of 9 Pages | 789.0K | 0.60% | — | 13.00 | 789.0K | — | OO | — | 2021-02-12 | ↗ |
| 28 | of 10 Pages | 719.3K | 0.60% | — | 13.00 | 719.3K | — | OO | United States of America and Israel | 2020-02-13 | ↗ |
| 29 | Bellco Legacy LLC | 40.0K | 0.03% | — | 40.0K | — | 40.0K | OO | — | 2022-02-14 | ↗ |
| 30 | 95-1411037 | 13.00 | 1.20% | 1.72M | — | 1.73M | — | IA | Delaware | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
59
-115 vs prev Q
New positions
12
Closed positions
122
Increased
32
Reduced
10
Put/Call ratio
0.00
Calls held
2.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 2.55M +2.5M (+100.0%) | 3.49B +3.5B (+100.0%) | 1.15% +1.147 pp | 3.45% +3.450 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 146.8K +146.8K (+100.0%) | 201.00M +201.0M (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 3 | PFIZER INC | 22.03M +— (+0.0%) | 30.18M +2.9M (+10.5%) | 9.92% -0.141 pp | 12.76% +6.519 pp | USD2.13 -35.7% | 5 qtrs — |
| 4 | TPG GP A, LLC | 18.72M +— (+0.0%) | 25.64M +2.4M (+10.5%) | 8.43% -0.120 pp | 0.95% -0.310 pp | USD14.92 -90.8% | 17 qtrs — |
| 5 | BLACKROCK, INC. | 17.68M +161.4K (+0.9%) | 24.22M +2.5M (+11.5%) | 7.96% -0.039 pp | 0.00% +0.000 pp | USD2.78 -50.7% | 6 qtrs — |
| 6 | CITADEL ADVISORS LLC | 12.11M -1.9M (-13.3%) | 16.59M -732.1K (-4.2%) | 5.45% -0.927 pp | 0.00% 0.000 pp | USD2.40 -42.9% | 29 qtrs — |
| 7 | VANGUARD GROUP INC | 9.25M +230.8K (+2.6%) | 12.67M +1.5M (+13.3%) | 4.17% +0.046 pp | 0.00% +0.000 pp | USD16.81 -91.9% | 29 qtrs — |
| 8 | PRIMECAP MANAGEMENT CO/CA/ | 8.14M +1.1M (+15.0%) | 11.15M +2.4M (+27.0%) | 3.67% +0.432 pp | 0.01% +0.002 pp | USD11.92 -88.5% | 21 qtrs — |
| 9 | PATIENT SQUARE CAPITAL LP | 4.96M +2.0M (+66.5%) | 6.80M +3.1M (+83.9%) | 2.24% +0.874 pp | 1.46% +0.467 pp | USD1.59 -13.8% | 5 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 3.93M +99.0K (+2.6%) | 5.39M +634.1K (+13.3%) | 1.77% +0.020 pp | 0.00% +0.000 pp | USD11.63 -88.2% | 29 qtrs — |
| 11 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 3.87M +— (+0.0%) | 5.30M +502.9K (+10.5%) | 1.74% -0.025 pp | 0.14% -0.001 pp | USD3.62 -62.2% | 8 qtrs — |
| 12 | WOODLINE PARTNERS LP | 3.50M -860.1K (-19.7%) | 4.80M -611.5K (-11.3%) | 1.58% -0.415 pp | 0.02% -0.007 pp | USD5.88 -76.7% | 23 qtrs — |
| 13 | TWO SIGMA INVESTMENTS, LP | 3.42M +39.8K (+1.2%) | 4.69M +494.4K (+11.8%) | 1.54% -0.004 pp | 0.01% +0.000 pp | USD2.83 -51.6% | 23 qtrs — |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.21M -468.2K (-12.7%) | 4.40M -163.0K (-3.6%) | 1.45% -0.234 pp | 0.00% +0.000 pp | USD10.68 -87.2% | 29 qtrs — |
| 15 | WILDCAT CAPITAL MANAGEMENT, LLC | 2.92M +— (+0.0%) | 4.00M +379.7K (+10.5%) | 1.32% -0.019 pp | 2.93% +0.436 pp | USD16.84 -91.9% | 27 qtrs — |
| 16 | TWO SIGMA ADVISERS, LP | 2.89M +108.6K (+3.9%) | 3.96M +510.4K (+14.8%) | 1.30% +0.031 pp | 0.01% +0.001 pp | USD2.93 -53.2% | 16 qtrs — |
| 17 | STATE STREET CORP | 2.76M +6.0K (+0.2%) | 3.78M +366.4K (+10.7%) | 1.24% -0.015 pp | 0.00% +0.000 pp | USD6.72 -79.6% | 29 qtrs — |
| 18 | CANDRIAM S.C.A. | 2.31M +2.3M (+100.0%) | 3.16M +3.2M (+100.0%) | 1.04% +1.038 pp | 0.02% +0.016 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 19 | GOLDMAN SACHS GROUP INC | 2.29M +1.1M (+90.2%) | 3.14M +1.6M (+110.1%) | 1.03% +0.481 pp | 0.00% +0.000 pp | USD2.34 -41.5% | 29 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 2.19M -706.7K (-24.4%) | 3.00M -592.0K (-16.5%) | 0.99% -0.337 pp | 0.00% 0.000 pp | USD1.57 -12.7% | 13 qtrs — |
| 21 | JANE STREET GROUP, LLC | 2.16M +944.6K (+77.7%) | 2.96M +1.5M (+96.3%) | 0.97% +0.418 pp | 0.00% +0.000 pp | USD1.37 +0.0% | 23 qtrs — |
| 22 | ABRDN PLC | 2.09M +504.1K (+31.9%) | 2.86M +896.3K (+45.7%) | 0.94% +0.217 pp | 0.00% +0.001 pp | USD1.48 -7.4% | 5 qtrs — |
| 23 | MILLENNIUM MANAGEMENT LLC | 1.84M -1.5M (-45.7%) | 2.52M -1.7M (-40.0%) | 0.83% -0.719 pp | 0.00% -0.001 pp | USD1.22 +12.3% | 25 qtrs — |
| 24 | FMR LLC | 1.45M +734.8K (+103.4%) | 1.98M +1.1M (+124.7%) | 0.65% +0.326 pp | 0.00% +0.000 pp | USD3.13 -56.2% | 29 qtrs — |
| 25 | AQR CAPITAL MANAGEMENT LLC | 1.43M -424.3K (-22.9%) | 1.96M -340.3K (-14.8%) | 0.64% -0.203 pp | 0.00% 0.000 pp | USD1.25 +9.6% | 7 qtrs — |
| 26 | UBS GROUP AG | 1.39M -2.2M (-61.1%) | 1.90M -2.5M (-57.0%) | 0.63% -1.005 pp | 0.00% 0.000 pp | USD1.90 -27.9% | 29 qtrs — |
| 27 | DAFNA CAPITAL MANAGEMENT LLC | 1.38M +— (+0.0%) | 1.89M +179.4K (+10.5%) | 0.62% -0.009 pp | 0.44% +0.016 pp | USD2.37 -42.2% | 7 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.36M +190.5K (+16.4%) | 1.86M +412.5K (+28.5%) | 0.61% +0.078 pp | 0.00% +0.000 pp | USD12.44 -89.0% | 29 qtrs — |
| 29 | D. E. SHAW & CO., INC. | 1.28M +819.1K (+176.6%) | 1.76M +1.2M (+205.6%) | 0.58% +0.366 pp | 0.00% +0.001 pp | USD1.32 +3.8% | 2 qtrs — |
| 30 | NORTHERN TRUST CORP | 1.20M -81.2K (-6.3%) | 1.64M +55.2K (+3.5%) | 0.54% -0.045 pp | 0.00% +0.000 pp | USD13.43 -89.8% | 29 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 1.01M +33.0K (+3.4%) | 1.38M +171.9K (+14.2%) | 0.45% +0.009 pp | 0.00% +0.000 pp | USD3.70 -63.0% | 29 qtrs — |
| 32 | ACADIAN ASSET MANAGEMENT LLC | 995.1K +461.3K (+86.4%) | 1.36M +701.0K (+106.4%) | 0.45% +0.204 pp | 0.00% +0.001 pp | USD1.29 +6.2% | 3 qtrs — |
| 33 | JPMORGAN CHASE & CO | 979.1K +70.4K (+7.7%) | 1.34M +214.6K (+19.0%) | 0.44% +0.026 pp | 0.00% +0.000 pp | USD11.79 -88.4% | 29 qtrs — |
| 34 | DIMENSIONAL FUND ADVISORS LP | 957.8K -1.1M (-54.2%) | 1.31M -1.3M (-49.4%) | 0.43% -0.524 pp | 0.00% 0.000 pp | USD5.81 -76.4% | 22 qtrs — |
| 35 | BNP PARIBAS ARBITRAGE, SNC | 900.4K +6.1K (+0.7%) | 1.23M +124.6K (+11.2%) | 0.41% -0.003 pp | 0.00% +0.000 pp | USD2.15 -36.3% | 27 qtrs — |
| 36 | RAIFFEISEN BANK INTERNATIONAL AG | 900.0K +450.0K (+100.0%) | 1.18M +607.5K (+106.3%) | 0.41% +0.200 pp | 0.02% +0.008 pp | USD1.70 -19.4% | 5 qtrs — |
| 37 | MORGAN STANLEY | 703.1K -596.0K (-45.9%) | 963.3K -647.7K (-40.2%) | 0.32% -0.277 pp | 0.00% +0.000 pp | USD2.85 -51.9% | 29 qtrs — |
| 38 | BARCLAYS PLC | 642.7K +299.7K (+87.4%) | 880.5K -79.8K (-8.3%) | 0.29% +0.133 pp | 0.00% +0.000 pp | USD2.47 -44.5% | 29 qtrs — |
| 39 | GSA CAPITAL PARTNERS LLP | 614.0K +431.1K (+235.7%) | 841.0K +614.0K (+270.5%) | 0.28% +0.193 pp | 0.07% +0.054 pp | USD1.40 -2.1% | 4 qtrs — |
| 40 | INVESCO LTD. | 609.8K +84.5K (+16.1%) | 835.4K +184.0K (+28.3%) | 0.27% +0.035 pp | 0.00% +0.000 pp | USD2.98 -54.0% | 24 qtrs — |
| 41 | CITIGROUP INC | 592.0K -2.1K (-0.4%) | 811.0K +74.3K (+10.1%) | 0.27% -0.005 pp | 0.00% +0.000 pp | USD2.76 -50.4% | 29 qtrs — |
| 42 | MAN GROUP PLC | 526.1K +244.1K (+86.5%) | 720.8K +371.0K (+106.1%) | 0.24% +0.108 pp | 0.00% +0.001 pp | USD1.36 +0.7% | 4 qtrs — |
| 43 | XTX TOPCO LTD | 476.3K -297.9K (-38.5%) | 652.5K -307.5K (-32.0%) | 0.21% -0.139 pp | 0.02% -0.033 pp | USD1.26 +8.7% | 5 qtrs — |
| 44 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 484.6K -5.4K (-1.1%) | 637.8K +30.3K (+5.0%) | 0.22% -0.006 pp | 0.00% +0.000 pp | USD6.69 -79.5% | 28 qtrs — |
| 45 | IEQ CAPITAL, LLC | 435.3K +59.2K (+15.7%) | 596.3K +130.0K (+27.9%) | 0.20% +0.024 pp | 0.00% +0.000 pp | USD2.77 -50.5% | 25 qtrs — |
| 46 | TD ASSET MANAGEMENT INC | 414.1K +— (+0.0%) | 567.3K +53.8K (+10.5%) | 0.19% -0.003 pp | 0.00% +0.000 pp | USD7.50 -81.7% | 29 qtrs — |
| 47 | BANK OF NEW YORK MELLON CORP | 405.8K +4.0K (+1.0%) | 556.0K +57.7K (+11.6%) | 0.18% -0.001 pp | 0.00% +0.000 pp | USD15.32 -91.1% | 29 qtrs — |
| 48 | ALLIANCEBERNSTEIN L.P. | 296.5K +— (+0.0%) | 406.2K +38.5K (+10.5%) | 0.13% -0.002 pp | 0.00% +0.000 pp | USD5.07 -73.0% | 29 qtrs — |
| 49 | MARSHALL WACE, LLP | 285.6K +285.6K (+100.0%) | 391.2K +391.2K (+100.0%) | 0.13% +0.129 pp | 0.00% +0.000 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 50 | QUADRATURE CAPITAL LTD | 274.4K +36.5K (+15.3%) | 376.0K +82.1K (+27.9%) | 0.12% +0.015 pp | 0.00% +0.000 pp | USD1.28 +7.0% | 4 qtrs — |
| 51 | CREATIVE PLANNING | 273.4K +219.8K (+409.8%) | 374.5K +308.0K (+463.2%) | 0.12% +0.099 pp | 0.00% +0.000 pp | USD1.56 -12.2% | 29 qtrs — |
| 52 | NUVEEN, LLC | 272.0K +— (+0.0%) | 372.6K +35.4K (+10.5%) | 0.12% -0.002 pp | 0.00% +0.000 pp | USD1.39 -1.4% | 4 qtrs — |
| 53 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 250.0K +— (+0.0%) | 342.5K +32.5K (+10.5%) | 0.11% -0.002 pp | 0.01% +0.001 pp | USD1.24 +10.5% | 2 qtrs — |
| 54 | RHUMBLINE ADVISERS | 203.0K -7.7K (-3.7%) | 278.1K +16.8K (+6.4%) | 0.09% -0.005 pp | 0.00% +0.000 pp | USD14.02 -90.2% | 29 qtrs — |
| 55 | WELLS FARGO & COMPANY/MN | 200.3K +55.4K (+38.3%) | 274.4K +94.8K (+52.7%) | 0.09% +0.024 pp | 0.00% +0.000 pp | USD2.69 -49.1% | 29 qtrs — |
| 56 | ALGERT GLOBAL LLC | 196.4K +196.4K (+100.0%) | 269.0K +269.0K (+100.0%) | 0.09% +0.089 pp | 0.00% +0.004 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 57 | HAROLD DAVIDSON & ASSOCIATES INC. | 194.8K -100.7K (-34.1%) | 266.8K -99.5K (-27.2%) | 0.09% -0.047 pp | 0.12% -0.048 pp | USD1.62 -15.4% | 5 qtrs — |
| 58 | ZACKS INVESTMENT MANAGEMENT | 192.7K -333.4K (-63.4%) | 264.0K -388.4K (-59.5%) | 0.09% -0.154 pp | 0.00% -0.003 pp | USD2.66 -48.5% | 9 qtrs — |
| 59 | VIRTUS INVESTMENT ADVISERS, INC. | 176.2K +94.9K (+116.8%) | 241.4K +140.6K (+139.5%) | 0.08% +0.042 pp | 0.07% +0.037 pp | USD1.39 -1.4% | 4 qtrs — |
| 60 | LPL FINANCIAL LLC | 170.8K -6.8K (-3.8%) | 233.9K +13.8K (+6.3%) | 0.08% -0.004 pp | 0.00% +0.000 pp | USD2.92 -53.1% | 11 qtrs — |
| 61 | PARTNERS CAPITAL INVESTMENT GROUP, LLP | 161.6K +— (+0.0%) | 221.4K +21.0K (+10.5%) | 0.07% -0.001 pp | 0.01% +0.000 pp | USD2.30 -40.4% | 25 qtrs — |
| 62 | GRAHAM CAPITAL MANAGEMENT, L.P. | 148.7K -48.6K (-24.7%) | 203.7K -41.0K (-16.8%) | 0.07% -0.023 pp | 0.00% +0.001 pp | USD1.13 +21.2% | 5 qtrs — |
| 63 | HSBC HOLDINGS PLC | 148.1K +54.1K (+57.5%) | 198.5K +84.7K (+74.4%) | 0.07% +0.024 pp | 0.00% +0.000 pp | USD2.09 -34.4% | 10 qtrs — |
| 64 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 138.9K +— (+0.0%) | 187.5K +15.3K (+8.9%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD13.93 -90.2% | 27 qtrs — |
| 65 | DEUTSCHE BANK AG\ | 131.1K -9.7K (-6.9%) | 179.6K +5.0K (+2.9%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD1.73 -20.8% | 29 qtrs — |
| 66 | SQUAREPOINT OPS LLC | 104.7K -163.4K (-61.0%) | 143.4K -189.0K (-56.9%) | 0.05% -0.075 pp | 0.00% 0.000 pp | USD1.26 +8.7% | 7 qtrs — |
| 67 | POINT72 ASSET MANAGEMENT, L.P. | 103.7K +103.7K (+100.0%) | 142.1K +142.1K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 68 | NWI MANAGEMENT LP | 100.0K +— (+0.0%) | 137.0K +13.0K (+10.5%) | 0.05% -0.001 pp | 0.01% 0.000 pp | USD1.13 +21.2% | 3 qtrs — |
| 69 | CERITY PARTNERS LLC | 97.9K -368.8K (-79.0%) | 134.1K -444.6K (-76.8%) | 0.04% -0.169 pp | 0.00% -0.001 pp | USD2.83 -51.6% | 20 qtrs — |
| 70 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 96.2K +48.2K (+100.4%) | 131.8K +72.3K (+121.4%) | 0.04% +0.021 pp | 0.00% +0.000 pp | USD1.63 -16.0% | 8 qtrs — |
| 71 | INTECH INVESTMENT MANAGEMENT LLC | 86.6K +14.7K (+20.5%) | 118.7K +29.5K (+33.1%) | 0.04% +0.006 pp | 0.00% +0.000 pp | USD1.97 -30.5% | 6 qtrs — |
| 72 | R SQUARED LTD | 86.2K +24.8K (+40.5%) | 118.1K +42.0K (+55.2%) | 0.04% +0.011 pp | 0.06% +0.022 pp | USD1.24 +10.5% | 5 qtrs — |
| 73 | HRT FINANCIAL LP | 72.8K -59.8K (-45.1%) | 99.0K -65.0K (-39.6%) | 0.03% -0.028 pp | 0.00% 0.000 pp | USD1.24 +10.5% | 2 qtrs — |
| 74 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 71.5K -93.3K (-56.6%) | 97.9K -106.4K (-52.1%) | 0.03% -0.043 pp | 0.00% 0.000 pp | USD2.29 -40.2% | 7 qtrs — |
| 75 | TUDOR INVESTMENT CORP ET AL | 71.0K +— (+0.0%) | 97.3K +9.2K (+10.5%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.46 -6.2% | 4 qtrs — |
| 76 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 70.4K +70.4K (+100.0%) | 96.5K +96.5K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.001 pp | USD1.37 +0.0% | 10 qtrs — |
| 77 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 67.8K -17.9K (-20.9%) | 92.9K -13.4K (-12.6%) | 0.03% -0.009 pp | 0.00% 0.000 pp | USD1.47 -6.8% | 7 qtrs — |
| 78 | CWM, LLC | 62.7K -1.6K (-2.5%) | 86.0K +6.0K (+7.5%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.25 +9.6% | 6 qtrs — |
| 79 | VONTOBEL HOLDING LTD. | 62.1K +— (+0.0%) | 85.1K +8.1K (+10.5%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD2.10 -34.8% | 15 qtrs — |
| 80 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 55.6K +3.5K (+6.7%) | 78.4K +8.0K (+11.4%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD1.32 +3.8% | 4 qtrs — |
| 81 | CAPTRUST FINANCIAL ADVISORS | 53.1K +37.4K (+237.9%) | 72.7K +53.3K (+273.3%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD1.33 +3.0% | 2 qtrs — |
| 82 | AQUATIC CAPITAL MANAGEMENT LLC | 51.9K +51.9K (+100.0%) | 71.1K +71.1K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.002 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 83 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 51.0K +11.2K (+28.2%) | 69.0K +19.0K (+38.0%) | 0.02% +0.005 pp | 0.00% +0.000 pp | USD3.13 -56.2% | 27 qtrs — |
| 84 | NAVALIGN, LLC | 49.4K -10.5K (-17.5%) | 67.7K -6.6K (-8.8%) | 0.02% -0.005 pp | 0.02% -0.003 pp | USD23.65 -94.2% | 19 qtrs — |
| 85 | ROYAL BANK OF CANADA | 48.8K -1.0M (-95.6%) | 67.0K -1.3M (-95.1%) | 0.02% -0.480 pp | 0.00% 0.000 pp | USD1.74 -21.3% | 29 qtrs — |
| 86 | SEI INVESTMENTS CO | 48.3K +— (+0.0%) | 66.2K +6.3K (+10.5%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD2.13 -35.7% | 5 qtrs — |
| 87 | HEADLANDS TECHNOLOGIES LLC | 46.8K -93.2K (-66.6%) | 64.1K -109.5K (-63.1%) | 0.02% -0.043 pp | 0.01% -0.009 pp | USD1.24 +10.5% | 2 qtrs — |
| 88 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 46.6K +— (+0.0%) | 63.8K +6.1K (+10.5%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.81 -24.3% | 5 qtrs — |
| 89 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 44.3K +20.3K (+84.4%) | 60.7K +30.9K (+103.7%) | 0.02% +0.009 pp | 0.01% -0.006 pp | USD1.30 +5.4% | 5 qtrs — |
| 90 | VIRTU FINANCIAL LLC | 42.4K +15.2K (+55.9%) | 58.0K +24.0K (+70.6%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD1.22 +12.3% | 3 qtrs — |
| 91 | ADVISOR GROUP HOLDINGS, INC. | 40.5K +— (+0.0%) | 55.4K +9.7K (+21.2%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD3.03 -54.8% | 24 qtrs — |
| 92 | RUSSELL INVESTMENTS GROUP, LTD. | 40.0K +18.2K (+83.3%) | 54.9K +27.8K (+102.5%) | 0.02% +0.008 pp | 0.00% +0.000 pp | USD1.30 +5.4% | 7 qtrs — |
| 93 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 39.8K +39.8K (+100.0%) | 54.5K +54.5K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 94 | CANADA PENSION PLAN INVESTMENT BOARD | 38.2K +38.2K (+100.0%) | 52.3K +52.3K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 95 | PROSHARE ADVISORS LLC | 38.0K +4.2K (+12.4%) | 52.1K +10.2K (+24.2%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD10.56 -87.0% | 25 qtrs — |
| 96 | CHOREO, LLC | 38.8K +38.8K (+100.0%) | 50.9K +50.9K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.001 pp | USD1.37 +0.0% | 1 qtrs NEW |
| 97 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 36.6K -2.3K (-5.8%) | 50.2K +1.9K (+4.0%) | 0.02% -0.001 pp | 0.00% 0.000 pp | USD3.31 -58.6% | 14 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 76 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 0.73% | 163.8K | 0.45% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.65% | 372.9K | 0.65% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 0.35% | 753.8K | 0.50% |
| 4 | AGF U.S. Market Neutral Anti-Beta Fund BTAL | 0.27% | 736.8K | 1.43% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.23% | 81.1K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.23% | 24.35M | 0.35% |
| 7 | Horizon Kinetics Medical ETF MEDX | 0.18% | 33.6K | 0.85% |
| 8 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.10% | 2.62M | 0.20% |
| 9 | Fidelity Enhanced Small Cap ETF FESM | 0.06% | 3.47M | 0.28% |
| 10 | Vanguard U.S. Momentum Factor ETF VFMO | 0.06% | 987.7K | 0.13% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
9.6K
Cash buys
—
Cash sales
1.00
Net activity
-9,586
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Yoshiyama Annie | Officer | S-Sale | D | Common Stock | 9,586 | 2.31 | 22.1K | 124,517 | D | ↗ |
| 2026-03-31 | Beneski Benjamin Machinas | Officer | S-Sale | D | Common Stock | 2,867 | 2.50 | 7.2K | 195,338 | D | ↗ |
| 2026-03-16 | Chang David D | Director / Officer | S-Sale | D | Common Stock | 47,763 | 2.47 | 118.0K | 5,150,599 | D | ↗ |
| 2026-03-16 | Beneski Benjamin Machinas | Officer | S-Sale | D | Common Stock | 4,835 | 2.47 | 11.9K | 198,205 | D | ↗ |
| 2026-03-02 | Beneski Benjamin Machinas | Officer | S-Sale | D | Common Stock | 7,132 | 2.60 | 18.5K | 203,040 | D | ↗ |
| 2026-02-02 | Yoshiyama Annie | Officer | A-Award | A | Restricted Stock Unit | 50,827 | 0.00 | — | 50,827 | D | ↗ |
| 2026-02-02 | Roberts Zachary | Officer | A-Award | A | Restricted Stock Unit | 203,307 | 0.00 | — | 203,307 | D | ↗ |
| 2026-02-02 | Parker Geoffrey M. | Officer | A-Award | A | Restricted Stock Unit | 152,480 | 0.00 | — | 152,480 | D | ↗ |
| 2026-02-02 | Douglas Earl Martin | Officer | A-Award | A | Stock Option (Right to buy) | 539,072 | 1.87 | 1.01M | 539,072 | D | ↗ |
| 2026-02-02 | Chang David D | Director / Officer | A-Award | A | Restricted Stock Unit | 392,586 | 0.00 | — | 392,586 | D | ↗ |
| 2026-02-02 | Beneski Benjamin Machinas | Officer | A-Award | A | Restricted Stock Unit | 105,720 | 0.00 | — | 105,720 | D | ↗ |
| 2026-02-02 | Belldegrun Arie | Director | A-Award | A | Restricted Stock Unit | 263,033 | 0.00 | — | 263,033 | D | ↗ |
| 2026-01-21 | Roberts Zachary | Officer | S-Sale | D | Common Stock | 26,269 | 1.56 | 41.0K | 616,866 | D | ↗ |
| 2025-12-18 | Kazam Joshua A | Director | M-Exempt | A | Common Stock | 47,700 | 0.00 | — | 350,763 | D | ↗ |
| 2025-11-17 | Beneski Benjamin Machinas | Officer | S-Sale | D | Common Stock | 786 | 1.22 | 958.92 | 217,721 | D | ↗ |
| 2025-10-21 | Parker Geoffrey M. | Officer | S-Sale | D | Common Stock | 36,744 | 1.26 | 46.2K | 1,276,796 | D | ↗ |
| 2025-06-18 | WITTE OWEN N. | Director | A-Award | A | Restricted Stock Unit | 95,400 | 0.00 | — | 95,400 | D | ↗ |
| 2025-06-18 | SATO VICKI L | Director | A-Award | A | Stock Option (Right to buy) | 144,400 | 1.29 | 186.3K | 144,400 | D | ↗ |
| 2025-06-18 | Mayo Stephen | Director | A-Award | A | Restricted Stock Unit | 95,400 | 0.00 | — | 95,400 | D | ↗ |
| 2025-06-18 | MESSEMER DEBORAH M. | Director | A-Award | A | Restricted Stock Unit | 95,400 | 0.00 | — | 95,400 | D | ↗ |
| 2025-06-18 | Kazam Joshua A | Director | A-Award | A | Restricted Stock Unit | 94,500 | 0.00 | — | 94,500 | D | ↗ |
| 2025-06-18 | Humer Franz B | Director | A-Award | A | Restricted Stock Unit | 95,400 | 0.00 | — | 95,400 | D | ↗ |
| 2025-06-18 | Barrett Elizabeth A. | Director | A-Award | A | Restricted Stock Unit | 95,400 | 0.00 | — | 95,400 | D | ↗ |
| 2025-06-10 | MESSEMER DEBORAH M. | Director | S-Sale | D | Common Stock | 36,885 | 1.42 | 52.4K | 107,431 | D | ↗ |
| 2025-04-21 | Yoshiyama Annie | Officer | S-Sale | D | Common Stock | 9,601 | 1.41 | 13.5K | 130,663 | D | ↗ |
| 2025-03-14 | Chang David D | Director / Officer | S-Sale | D | Common Stock | 46,668 | 1.96 | 91.5K | 5,276,569 | D | ↗ |
| 2025-03-14 | Beneski Benjamin Machinas | Officer | S-Sale | D | Common Stock | 5,488 | 1.98 | 10.8K | 218,507 | D | ↗ |
| 2025-03-01 | Beneski Benjamin Machinas | Officer | — | — | Stock Option (Right to buy) | 54,314 | 13.31 | 722.9K | 0 | D | ↗ |
| 2025-02-18 | MESSEMER DEBORAH M. | Director | S-Sale | D | Common Stock | 13,313 | 2.43 | 32.4K | 144,316 | D | ↗ |
| 2025-02-03 | Roberts Zachary | Officer | S-Sale | D | Common Stock | 18,832 | 1.70 | 32.0K | 643,135 | D | ↗ |
| 2025-02-03 | Parker Geoffrey M. | Officer | S-Sale | D | Common Stock | 4,361 | 1.73 | 7.5K | 1,301,540 | D | ↗ |
| 2025-02-03 | MOORE TIMOTHY L. | Officer | S-Sale | D | Common Stock | 14,746 | 1.71 | 25.2K | 250,713 | D | ↗ |
| 2025-02-03 | Douglas Earl Martin | Officer | S-Sale | D | Common Stock | 6,404 | 1.71 | 11.0K | 587,848 | D | ↗ |
| 2025-02-03 | Chang David D | Director / Officer | S-Sale | D | Common Stock | 46,003 | 1.68 | 77.3K | 5,317,237 | D | ↗ |
| 2025-01-24 | Yoshiyama Annie | Officer | A-Award | A | Stock Option (Right to buy) | 128,093 | 1.94 | 248.5K | 128,093 | D | ↗ |
| 2025-01-24 | Roberts Zachary | Officer | A-Award | A | Common Stock | 173,913 | 0.00 | — | 661,967 | D | ↗ |
| 2025-01-24 | Parker Geoffrey M. | Officer | A-Award | A | Stock Option (Right to buy) | 614,844 | 1.94 | 1.19M | 614,844 | D | ↗ |
| 2025-01-24 | Douglas Earl Martin | Officer | A-Award | A | Stock Option (Right to buy) | 512,370 | 1.94 | 994.0K | 512,370 | D | ↗ |
| 2025-01-24 | Chang David D | Director / Officer | A-Award | A | Common Stock | 552,174 | 0.00 | — | 5,363,240 | D | ↗ |
| 2025-01-24 | Belldegrun Arie | Director | A-Award | A | Stock Option (Right to buy) | 1,307,927 | 1.94 | 2.54M | 1,307,927 | D | ↗ |
| 2025-01-21 | Roberts Zachary | Officer | S-Sale | D | Common Stock | 27,199 | 1.78 | 48.4K | 488,054 | D | ↗ |
| 2024-12-09 | MESSEMER DEBORAH M. | Director | S-Sale | D | Common Stock | 9,136 | 2.18 | 19.9K | 157,629 | D | ↗ |
| 2024-12-05 | Humer Franz B | Director | S-Sale | D | Common Stock | 9,221 | 2.16 | 19.9K | 307,507 | D | ↗ |
| 2024-10-21 | Parker Geoffrey M. | Officer | F-InKind | D | Common Stock | 36,404 | 2.84 | 103.4K | 1,131,988 | D | ↗ |
| 2024-08-21 | Douglas Earl Martin | Officer | F-InKind | D | Common Stock | 28,310 | 2.79 | 78.8K | 449,324 | — | ↗ |
| 2024-06-18 | MESSEMER DEBORAH M. | Director | S-Sale | D | Common Stock | 18,641 | 2.28 | 42.5K | 166,765 | — | ↗ |
| 2024-06-05 | Yoshiyama Annie | Officer | — | D | Stock Option (Right to buy) | 348,708 | 3.98 | 1.39M | 0 | — | ↗ |
| 2024-06-05 | WITTE OWEN N. | Director | A-Award | A | Stock Option (Right to buy) | 191,082 | 2.44 | 466.2K | 191,082 | — | ↗ |
| 2024-06-05 | SATO VICKI L | Director | A-Award | A | Stock Option (Right to buy) | 95,541 | 2.44 | 233.1K | 95,541 | — | ↗ |
| 2024-06-05 | Mayo Stephen | Director | A-Award | A | Stock Option (Right to buy) | 191,082 | 2.44 | 466.2K | 191,082 | — | ↗ |
| 2024-06-05 | MESSEMER DEBORAH M. | Director | A-Award | A | Common Stock | 122,950 | 0.00 | — | 185,406 | — | ↗ |
| 2024-06-05 | Kazam Joshua A | Director | A-Award | A | Stock Option (Right to buy) | 191,082 | 2.44 | 466.2K | 191,082 | — | ↗ |
| 2024-06-05 | Humer Franz B | Director | A-Award | A | Stock Option (Right to buy) | 95,541 | 2.44 | 233.1K | 95,541 | — | ↗ |
| 2024-06-05 | Barrett Elizabeth A. | Director | A-Award | A | Stock Option (Right to buy) | 191,082 | 2.44 | 466.2K | 191,082 | — | ↗ |
| 2024-05-30 | Humer Franz B | Director | S-Sale | D | Common Stock | 11,200 | 2.34 | 26.2K | 255,253 | — | ↗ |
| 2024-05-16 | Parker Geoffrey M. | Officer | A-Award | A | Common Stock | 344,828 | 2.90 | 1.00M | 1,164,418 | — | ↗ |
| 2024-05-16 | Chang David D | Director / Officer | A-Award | A | Common Stock | 344,828 | 2.90 | 1.00M | 4,810,106 | — | ↗ |
| 2024-05-16 | Belldegrun Arie | Director | A-Award | A | Common Stock | 344,828 | 2.90 | 1.00M | 539,867 | — | ↗ |
| 2024-04-22 | MOORE TIMOTHY L. | Officer | F-InKind | D | Common Stock | 17,360 | 3.47 | 60.2K | 265,459 | — | ↗ |
| 2024-03-14 | Chang David D | Director / Officer | F-InKind | D | Common Stock | 53,393 | 4.33 | 231.2K | 4,465,278 | — | ↗ |
| 2024-01-30 | Parker Geoffrey M. | Officer | P-Purchase | A | Common Stock | 190 | 3.60 | 683.05 | 819,590 | — | ↗ |
| 2024-01-25 | Roberts Zachary | Officer | A-Award | A | Stock Option (Right to buy) | 494,949 | 3.20 | 1.58M | 494,949 | — | ↗ |
| 2024-01-25 | Parker Geoffrey M. | Officer | A-Award | A | Stock Option (Right to buy) | 103,939 | 3.20 | 332.6K | 103,939 | — | ↗ |
| 2024-01-25 | MOORE TIMOTHY L. | Officer | A-Award | A | Common Stock | 96,600 | 0.00 | — | 282,819 | — | ↗ |
| 2024-01-25 | Douglas Earl Martin | Officer | A-Award | A | Stock Option (Right to buy) | 147,778 | 3.20 | 472.9K | 147,778 | — | ↗ |
| 2024-01-25 | Chang David D | Director / Officer | A-Award | A | Stock Option (Right to buy) | 1,123,535 | 3.20 | 3.60M | 1,123,535 | — | ↗ |
| 2024-01-25 | Belldegrun Arie | Director | A-Award | A | Common Stock | 211,973 | 0.00 | — | 1,866,859 | — | ↗ |
| 2024-01-22 | Roberts Zachary | Officer | F-InKind | D | Common Stock | 24,690 | 3.17 | 78.4K | 375,253 | — | ↗ |
| 2023-12-18 | MESSEMER DEBORAH M. | Director | S-Sale | D | Common Stock | 18,640 | 2.70 | 50.3K | 62,456 | — | ↗ |
| 2023-10-16 | Parker Geoffrey M. | Officer | A-Award | A | Stock Option (Right to Buy) | 950,000 | 3.24 | 3.08M | 950,000 | — | ↗ |
| 2023-08-14 | Douglas Earl Martin | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-10 | CHEN YINLIN JACK | Officer | A-Award | A | Common Stock | 11,401 | 0.00 | — | 88,881 | — | ↗ |
| 2023-08-07 | Mayo Stephen | Director | S-Sale | D | Common Stock | 10,000 | 4.29 | 42.9K | 25,328 | — | ↗ |
| 2023-06-13 | WITTE OWEN N. | Director | A-Award | A | Common Stock | 74,561 | 0.00 | — | 292,832 | — | ↗ |
| 2023-06-13 | SATO VICKI L | Director | A-Award | A | Common Stock | 59,649 | 0.00 | — | 101,100 | — | ↗ |
| 2023-06-13 | Mayo Stephen | Director | A-Award | A | Stock Option (Right to Buy) | 116,120 | 5.70 | 661.9K | 116,120 | — | ↗ |
| 2023-06-13 | MESSEMER DEBORAH M. | Director | A-Award | A | Common Stock | 74,561 | 0.00 | — | 81,096 | — | ↗ |
| 2023-06-13 | Kazam Joshua A | Director | A-Award | A | Stock Option (Right to Buy) | 116,120 | 5.70 | 661.9K | 116,120 | — | ↗ |
| 2023-06-13 | Humer Franz B | Director | A-Award | A | Common Stock | 74,561 | 0.00 | — | 266,453 | — | ↗ |
| 2023-06-13 | Barrett Elizabeth A. | Director | A-Award | A | Stock Option (Right to Buy) | 116,120 | 5.70 | 661.9K | 116,120 | — | ↗ |
| 2023-04-24 | MOORE TIMOTHY L. | Officer | A-Award | A | Stock Option (Right to Buy) | 831,024 | 5.37 | 4.46M | 831,024 | — | ↗ |
| 2023-04-01 | Smith Lillian | Officer | — | D | Stock Option (Right to Buy) | 24,428 | 5.04 | 123.1K | 0 | — | ↗ |
| 2023-03-22 | SCHMIDT ERIC THOMAS | Officer | A-Award | A | Common Stock | 558,094 | 0.00 | — | 862,439 | — | ↗ |
| 2023-03-22 | Roberts Zachary | Officer | A-Award | A | Common Stock | 148,035 | 0.00 | — | 399,943 | — | ↗ |
| 2023-03-22 | MOORE ALISON | Officer | A-Award | A | Stock Option (Right to buy) | 432,738 | 5.04 | 2.18M | 432,738 | — | ↗ |
| 2023-03-22 | Chang David D | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,492,200 | 5.04 | 7.52M | 1,492,200 | — | ↗ |
| 2023-03-22 | Belldegrun Arie | Director | A-Award | A | Stock Option (Right to Buy) | 994,800 | 5.04 | 5.01M | 994,800 | — | ↗ |
| 2023-03-14 | SCHMIDT ERIC THOMAS | Officer | F-InKind | D | Common Stock | 35,879 | 5.47 | 196.3K | 304,345 | — | ↗ |
| 2023-03-14 | MOORE ALISON | Officer | F-InKind | D | Common Stock | 8,351 | 5.51 | 46.0K | 114,637 | — | ↗ |
| 2023-03-14 | Chang David D | Director / Officer | F-InKind | D | Common Stock | 22,340 | 5.56 | 124.2K | 2,269,447 | — | ↗ |
| 2023-03-14 | Bhavnagri Veer | Officer | F-InKind | D | Common Stock | 23,628 | 5.67 | 134.0K | 556,049 | — | ↗ |
| 2023-02-13 | Bhavnagri Veer | Officer | S-Sale | D | Common Stock | 3,000 | 6.85 | 20.6K | 577,677 | — | ↗ |
| 2023-01-20 | Roberts Zachary | Officer | A-Award | A | Stock Option (Right to Buy) | 873,015 | 0.00 | — | 873,015 | — | ↗ |
| 2023-01-17 | Bhavnagri Veer | Director | S-Sale | D | Common Stock | 3,000 | 7.04 | 21.1K | 580,677 | — | ↗ |
| 2023-01-03 | Roberts Zachary | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-12-15 | Bhavnagri Veer | Director | S-Sale | D | Common Stock | 5,602 | 7.53 | 42.2K | 583,677 | — | ↗ |
| 2022-10-07 | Amado Rafael | Director | A-Award | A | Common Stock | 19,120 | 0.00 | — | 550,410 | — | ↗ |
| 2022-10-03 | Amado Rafael | Director | F-InKind | D | Common Stock | 8,968 | 11.06 | 99.2K | 531,290 | — | ↗ |
| 2022-08-11 | WITTE OWEN N. | Director | S-Sale | D | Common Stock | 5,000 | 17.25 | 86.3K | 218,271 | — | ↗ |
| 2022-08-02 | Amado Rafael | Officer | S-Sale | D | Common Stock | 2,000 | 11.97 | 23.9K | 540,257 | — | ↗ |
| 2022-07-08 | Mayo Stephen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-05 | Amado Rafael | Officer | S-Sale | D | Common Stock | 2,000 | 11.44 | 22.9K | 542,257 | — | ↗ |
| 2022-06-22 | WITTE OWEN N. | Director | S-Sale | D | Common Stock | 10,000 | 11.76 | 117.6K | 233,271 | — | ↗ |
| 2022-06-21 | Amado Rafael | Director | S-Sale | D | Common Stock | 2,000 | 11.18 | 22.4K | 544,257 | — | ↗ |
| 2022-06-15 | WITTE OWEN N. | Director | A-Award | A | Stock Option (Right to Buy) | 35,535 | 9.62 | 341.8K | 35,535 | — | ↗ |
| 2022-06-15 | SATO VICKI L | Director | A-Award | A | Stock Option (Right to Buy) | 35,535 | 9.62 | 341.8K | 35,535 | — | ↗ |
| 2022-06-15 | MESSEMER DEBORAH M. | Director | A-Award | A | Stock Option (Right to Buy) | 71,070 | 0.00 | — | 71,070 | — | ↗ |
| 2022-06-15 | Kazam Joshua A | Director | A-Award | A | Common Stock | 44,178 | 0.00 | — | 303,063 | — | ↗ |
| 2022-06-15 | Humer Franz B | Director | A-Award | A | Common Stock | 44,178 | 0.00 | — | 191,892 | — | ↗ |
| 2022-06-15 | Barrett Elizabeth A. | Director | A-Award | A | Stock Option (Right to Buy) | 71,070 | 9.62 | 683.7K | 71,070 | — | ↗ |
| 2022-05-19 | Amado Rafael | Director | S-Sale | D | Common Stock | 11,500 | 7.40 | 85.1K | 546,257 | — | ↗ |
| 2022-03-31 | PF Equity Holdings 2 B.V. | Director | J-Other | D | Common Stock | 22,032,040 | 0.00 | — | 0 | — | ↗ |
| 2022-03-23 | SCHMIDT ERIC THOMAS | Director / Officer | A-Award | A | Common Stock | 237,358 | 0.00 | — | 337,904 | — | ↗ |
| 2022-03-23 | MOORE ALISON | Officer | A-Award | A | Stock Option (Right to Buy) | 737,179 | 9.69 | 7.14M | 737,179 | — | ↗ |
| 2022-03-23 | Chang David D | Director | A-Award | A | Stock Option (Right to Buy) | 2,195,512 | 0.00 | — | 2,195,512 | — | ↗ |
| 2022-03-23 | Bhavnagri Veer | Director | A-Award | A | Stock Option (Right to Buy) | 272,435 | 0.00 | — | 272,435 | — | ↗ |
| 2022-03-23 | Belldegrun Arie | Director | A-Award | A | Stock Option (Right to Buy) | 1,458,333 | 0.00 | — | 1,458,333 | — | ↗ |
| 2022-03-23 | Amado Rafael | Director | A-Award | A | Common Stock | 237,358 | 0.00 | — | 557,477 | — | ↗ |
| 2022-03-15 | SCHMIDT ERIC THOMAS | Director / Officer | S-Sale | D | Common Stock | 11,469 | 7.63 | 87.6K | 100,546 | — | ↗ |
| 2022-03-15 | MOORE ALISON | Director / Officer | S-Sale | D | Common Stock | 8,698 | 7.63 | 66.4K | 120,430 | — | ↗ |
| 2022-03-15 | Chang David D | Director | S-Sale | D | Common Stock | 23,648 | 7.65 | 180.9K | 2,289,652 | — | ↗ |
| 2022-03-15 | Bhavnagri Veer | Director | S-Sale | D | Common Stock | 8,849 | 7.68 | 68.0K | 413,841 | — | ↗ |
| 2022-03-15 | Amado Rafael | Director | S-Sale | D | Common Stock | 5,169 | 7.71 | 39.8K | 320,119 | — | ↗ |
| 2022-03-14 | Belldegrun Arie | Director | J-Other | D | Common Stock | 4,710,121 | 0.00 | — | 0 | — | ↗ |
| 2022-03-07 | Kazam Joshua A | Director | J-Other | A | Common Stock | 412,618 | 0.00 | — | 671,503 | — | ↗ |
| 2022-01-12 | TPG GP A, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 18,716,306 | — | ↗ |
| 2022-01-12 | Kazam Joshua A | Director | P-Purchase | A | Common Stock | 15,000 | 12.60 | 189.0K | 258,885 | — | ↗ |
| 2022-01-12 | Belldegrun Arie | Director | P-Purchase | A | Common Stock | 155,039 | 12.60 | 1.95M | 195,039 | — | ↗ |
| 2021-10-01 | Amado Rafael | Officer | S-Sale | D | Common Stock | 11,507 | 24.35 | 280.2K | 323,928 | — | ↗ |
| 2021-09-15 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 5,000 | 2.27 | 11.4K | 426,669 | — | ↗ |
| 2021-09-10 | PF Equity Holdings 2 B.V. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 22,032,040 | — | ↗ |
| 2021-09-09 | WITTE OWEN N. | Director | S-Sale | D | Common Stock | 5,000 | 25.54 | 127.7K | 221,182 | — | ↗ |
| 2021-08-20 | WITTE OWEN N. | Director | S-Sale | D | Common Stock | 5,000 | 23.70 | 118.5K | 231,182 | — | ↗ |
| 2021-08-16 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 5,000 | 2.27 | 11.4K | 426,353 | — | ↗ |
| 2021-07-30 | SATO VICKI L | Director | — | D | Stock Option (Right to Buy) | 3,000 | 36.31 | 108.9K | 0 | — | ↗ |
| 2021-07-30 | Barrett Elizabeth A. | Director | A-Award | A | Stock Option (Right to Buy) | 63,385 | 21.95 | 1.39M | 63,385 | — | ↗ |
| 2021-07-15 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 5,000 | 2.27 | 11.4K | 426,353 | — | ↗ |
| 2021-06-15 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 5,000 | 2.27 | 11.4K | 426,353 | — | ↗ |
| 2021-06-11 | Kazam Joshua A | Director | G-Gift | D | Common Stock | 500,000 | 0.00 | — | 243,885 | — | ↗ |
| 2021-06-10 | WITTE OWEN N. | Director | A-Award | A | Stock Option (Right to Buy) | 28,015 | 25.76 | 721.7K | 28,015 | — | ↗ |
| 2021-06-10 | MESSEMER DEBORAH M. | Director | A-Award | A | Stock Option (Right to Buy) | 28,015 | 25.76 | 721.7K | 28,015 | — | ↗ |
| 2021-06-10 | Kazam Joshua A | Director | A-Award | A | Common Stock | 16,498 | 0.00 | — | 743,885 | — | ↗ |
| 2021-06-10 | Humer Franz B | Director | A-Award | A | Common Stock | 16,498 | 0.00 | — | 147,714 | — | ↗ |
| 2021-06-09 | WITTE OWEN N. | Director | S-Sale | D | Common Stock | 9,969 | 25.05 | 249.7K | 236,182 | — | ↗ |
| 2021-05-24 | SCHMIDT ERIC THOMAS | Officer | M-Exempt | A | Common Stock | 14,897 | 18.22 | 271.4K | 110,994 | — | ↗ |
| 2021-05-24 | Chang David D | Director / Officer | M-Exempt | A | Common Stock | 27,410 | 18.22 | 499.4K | 2,312,279 | — | ↗ |
| 2021-05-24 | Belldegrun Arie | Director | M-Exempt | A | Common Stock | 379,066 | 18.22 | 6.91M | 583,034 | — | ↗ |
| 2021-05-18 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 5,000 | 2.27 | 11.4K | 426,353 | — | ↗ |
| 2021-05-18 | Amado Rafael | Officer | A-Award | A | Common Stock | 200,534 | 0.00 | — | 335,435 | — | ↗ |
| 2021-05-17 | Bhavnagri Veer | Officer | S-Sale | D | Common Stock | 5,000 | 28.30 | 141.5K | 421,353 | — | ↗ |
| 2021-04-15 | Bhavnagri Veer | Officer | S-Sale | D | Common Stock | 9,394 | 32.01 | 300.7K | 421,959 | — | ↗ |
| 2021-03-26 | SCHMIDT ERIC THOMAS | Officer | A-Award | A | Common Stock | 24,866 | 0.00 | — | 96,097 | — | ↗ |
| 2021-03-26 | MOORE ALISON | Officer | A-Award | A | Common Stock | 24,866 | 0.00 | — | 127,440 | — | ↗ |
| 2021-03-26 | Chang David D | Director / Officer | A-Award | A | Common Stock | 80,452 | 0.00 | — | 2,284,869 | — | ↗ |
| 2021-03-26 | Bhavnagri Veer | Officer | A-Award | A | Common Stock | 22,202 | 0.00 | — | 421,353 | — | ↗ |
| 2021-03-26 | Belldegrun Arie | Director | A-Award | A | Common Stock | 53,635 | 0.00 | — | 203,968 | — | ↗ |
| 2021-03-26 | Amado Rafael | Officer | A-Award | A | Common Stock | 24,866 | 0.00 | — | 134,901 | — | ↗ |
| 2021-03-15 | SCHMIDT ERIC THOMAS | Officer | S-Sale | D | Common Stock | 8,053 | 38.23 | 307.9K | 71,231 | — | ↗ |
| 2021-03-15 | MOORE ALISON | Officer | S-Sale | D | Common Stock | 6,164 | 38.14 | 235.1K | 102,574 | — | ↗ |
| 2021-03-15 | Chang David D | Director / Officer | S-Sale | D | Common Stock | 20,513 | 38.57 | 791.3K | 2,204,417 | — | ↗ |
| 2021-03-15 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 10,000 | 2.27 | 22.7K | 415,774 | — | ↗ |
| 2021-03-15 | Amado Rafael | Officer | S-Sale | D | Common Stock | 2,798 | 38.05 | 106.5K | 110,035 | — | ↗ |
| 2021-01-15 | SCHMIDT ERIC THOMAS | Officer | S-Sale | D | Common Stock | 11,053 | 32.40 | 358.2K | 1,152,995 | — | ↗ |
| 2021-01-14 | SCHMIDT ERIC THOMAS | Officer | S-Sale | D | Common Stock | 9,851 | 30.60 | 301.5K | 1,172,744 | — | ↗ |
| 2020-12-31 | Kazam Joshua A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-17 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 51,500 | 2.27 | 116.9K | 405,402 | — | ↗ |
| 2020-11-16 | SCHMIDT ERIC THOMAS | Officer | S-Sale | D | Common Stock | 4,634 | 32.60 | 151.1K | 1,192,961 | — | ↗ |
| 2020-10-21 | Kazam Joshua A | Director | — | D | Common Stock | 0 | 0.00 | — | 727,387 | — | ↗ |
| 2020-10-15 | SCHMIDT ERIC THOMAS | Officer | S-Sale | D | Common Stock | 3,479 | 41.33 | 143.8K | 1,199,794 | — | ↗ |
| 2020-10-13 | MOORE ALISON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,031 | 2.27 | 25.0K | 579,959 | — | ↗ |
| 2020-10-12 | MOORE ALISON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 24,233 | 2.27 | 55.0K | 590,990 | — | ↗ |
| 2020-10-09 | MOORE ALISON | Officer | M-Exempt | A | Common Stock | 30,199 | 2.27 | 68.6K | 147,879 | — | ↗ |
| 2020-10-08 | MOORE ALISON | Officer | S-Sale | D | Common Stock | 5,065 | 41.00 | 207.7K | 117,680 | — | ↗ |
| 2020-10-07 | Amado Rafael | Officer | S-Sale | D | Common Stock | 16,538 | 39.40 | 651.5K | 111,677 | — | ↗ |
| 2020-10-06 | MOORE ALISON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 35,264 | 2.27 | 80.0K | 650,487 | — | ↗ |
| 2020-10-06 | Bhavnagri Veer | Officer | M-Exempt | A | Common Stock | 10,000 | 2.27 | 22.7K | 363,902 | — | ↗ |
| 2020-10-01 | Bhavnagri Veer | Director | M-Exempt | A | Stock Option (Right to Buy) | 25,000 | 2.27 | 56.8K | 223,800 | — | ↗ |
| 2020-10-01 | Amado Rafael | Officer | S-Sale | D | Common Stock | 9,752 | 36.37 | 354.7K | 128,215 | — | ↗ |
| 2020-09-21 | SCHMIDT ERIC THOMAS | Officer | S-Sale | D | Common Stock | 9,889 | 34.76 | 343.7K | 1,217,706 | — | ↗ |
| 2020-09-01 | Bhavnagri Veer | Officer | S-Sale | D | Common Stock | 400 | 35.89 | 14.4K | 353,902 | — | ↗ |
| 2020-08-31 | Chang David D | Director / Officer | G-Gift | A | Common Stock | 205,778 | 0.00 | — | 856,044 | — | ↗ |
| 2020-08-13 | MOORE ALISON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 32,451 | 2.27 | 73.7K | 685,751 | — | ↗ |
| 2020-08-07 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 5,605 | 37.02 | 207.5K | 18,723,992 | — | ↗ |
| 2020-08-06 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | J-Other | D | Common Stock | 962,555 | 0.00 | — | 18,753,751 | — | ↗ |
| 2020-08-03 | Bhavnagri Veer | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 2.27 | 56.8K | 273,800 | — | ↗ |
| 2020-06-30 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 59,747 | 42.21 | 2.52M | 19,716,306 | — | ↗ |
| 2020-06-29 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 24,904 | 43.27 | 1.08M | 19,776,053 | — | ↗ |
| 2020-06-26 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 500 | 44.01 | 22.0K | 19,800,957 | — | ↗ |
| 2020-06-25 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 72,359 | 44.19 | 3.20M | 19,801,457 | — | ↗ |
| 2020-06-24 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 15,269 | 43.93 | 670.7K | 19,873,816 | — | ↗ |
| 2020-06-23 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 110,012 | 43.91 | 4.83M | 19,911,298 | — | ↗ |
| 2020-06-22 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 129,570 | 42.72 | 5.53M | 20,064,165 | — | ↗ |
| 2020-06-19 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 47,767 | 42.04 | 2.01M | 20,193,735 | — | ↗ |
| 2020-06-18 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 94,600 | 42.14 | 3.99M | 20,241,502 | — | ↗ |
| 2020-06-17 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 87,319 | 42.18 | 3.68M | 20,336,102 | — | ↗ |
| 2020-06-16 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 174,511 | 42.20 | 7.36M | 20,423,421 | — | ↗ |
| 2020-06-15 | TPG Group Holdings (SBS) Advisors, Inc. | 10% Owner | S-Sale | D | Common Stock | 129,154 | 42.14 | 5.44M | 20,597,932 | — | ↗ |
| 2020-06-05 | WITTE OWEN N. | Director | A-Award | A | Common Stock | 9,969 | 0.00 | — | 246,151 | — | ↗ |
| 2020-06-05 | MESSEMER DEBORAH M. | Director | A-Award | A | Stock Option (Right to Buy) | 16,640 | 42.63 | 709.4K | 16,640 | — | ↗ |
| 2020-06-05 | Kazam Joshua A | Director | A-Award | A | Common Stock | 9,969 | 0.00 | — | 1,033,305 | — | ↗ |
Executive team
Top executives
Shares Outstanding
243.87M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 724.0K | — | 1.07M | 2.59M | 400.0K | 14.2K | 6.14M | 59.64% | ↗ |
| 2 | 2025 | Zachary J. Roberts, M.D., Ph.D. Chief Medical Officer and Executive Vice President of Research and Development | 530.2K | — | 337.4K | 815.2K | 202.8K | 17.8K | 1.99M | 57.99% | ↗ |
| 3 | 2025 | Geoffrey Parker Executive Vice President and Chief Financial Officer | 500.0K | — | 337.4K | 815.2K | 191.3K | 15.8K | 1.94M | 59.29% | ↗ |
| 4 | 2024 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 724.0K | — | 1.02M | 2.40M | 329.4K | 10.1K | 4.48M | 76.27% | ↗ |
| 5 | 2024 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 724.0K | — | 1.02M | 2.40M | 329.4K | 10.1K | 3.47M | 98.66% | ↗ |
| 6 | 2024 | Zachary J. Roberts M.D., Ph.D. Chief Medical Officer and Executive Vice President of Research and Development | 530.2K | — | 448.0K | 1.06M | 167.0K | 17.5K | 2.22M | 67.82% | ↗ |
| 7 | 2024 | Zachary J. Roberts, M.D., Ph.D. Chief Medical Officer and Executive Vice President of Research and Development | 530.2K | — | 448.0K | 1.06M | 167.0K | 17.5K | 2.22M | 67.82% | ↗ |
| 8 | 2024 | Timothy Moore Former Executive Vice President and Chief Technology Officer | 525.0K | — | 309.1K | 730.0K | 165.4K | — | 1.73M | 60.08% | ↗ |
| 9 | 2023 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 724.0K | — | 8.00M | 5.07M | 270.6K | 2.0K | 14.06M | 92.91% | ↗ |
| 10 | 2023 | Zachary J. Roberts M.D., Ph.D. Chief Medical Officer and Executive Vice President of Research and Development | 522.8K | 75.0K | 3.53M | 3.85M | 134.7K | 16.9K | 8.13M | 90.79% | ↗ |
| 11 | 2023 | Zachary J. Roberts M.D., Ph.D. Chief Medical Officer and Executive Vice President of Research and Development | 522.8K | 75.0K | 3.53M | 3.85M | 134.7K | 14.9K | 8.13M | 90.81% | ↗ |
| 12 | 2023 | Timothy Moore Former Executive Vice President and Chief Technology Officer | 360.9K | 100.0K | 2.25M | 3.00M | 93.4K | — | 5.80M | 90.45% | ↗ |
| 13 | 2023 | Timothy Moore Chief Technology Officer | 360.9K | 100.0K | 2.25M | 3.00M | 93.4K | — | 5.80M | 90.45% | ↗ |
| 14 | 2022 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 724.0K | — | — | 13.70M | 376.5K | — | 14.80M | 92.56% | ↗ |
| 15 | 2022 | Eric Schmidt, Ph.D. Chief Financial Officer | 490.0K | — | 2.30M | 2.30M | 176.4K | 13.7K | 5.28M | 87.12% | ↗ |
| 16 | 2022 | Alison Moore, Ph.D. Chief Technical Officer | 490.0K | — | — | 4.60M | 176.4K | 13.7K | 5.28M | 87.12% | ↗ |
| 17 | 2022 | Rafael Amado, M.D. Former Executive Vice President of Research and Development | 633.6K | — | 2.30M | 2.30M | — | 11.5K | 5.24M | 87.70% | ↗ |
| 18 | 2022 | Veer Bhavnagri Former General Counsel | 480.0K | — | 1.70M | 1.70M | 172.8K | 13.7K | 4.07M | 83.61% | ↗ |
| 19 | 2021 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 695.0K | — | 2.72M | 6.35M | 396.2K | — | 10.16M | 89.26% | ↗ |
| 20 | 2021 | Rafael Amado, M.D. Former Executive Vice President of Research and Development | 571.6K | 100.0K | 6.84M | 1.96M | 228.0K | 11.1K | 9.71M | 90.62% | ↗ |
| 21 | 2021 | Rafael Amado, M.D. Chief Medical Officer and Executive Vice President of Research and Development | 571.6K | 100.0K | 6.84M | 1.96M | 228.0K | 11.1K | 9.71M | 90.62% | ↗ |
| 22 | 2021 | Alison Moore, Ph.D. Chief Technical Officer | 475.0K | 75.0K | 840.0K | 1.96M | 180.5K | 13.1K | 3.55M | 79.04% | ↗ |
| 23 | 2021 | Eric Schmidt, Ph.D. Chief Financial Officer | 475.0K | — | 840.0K | 1.96M | 180.5K | — | 3.46M | 81.05% | ↗ |
| 24 | 2021 | Veer Bhavnagri General Counsel | 464.0K | — | 750.0K | 1.75M | 176.3K | 13.1K | 3.16M | 79.30% | ↗ |
| 25 | 2021 | Veer Bhavnagri Former General Counsel | 464.0K | — | 750.0K | 1.75M | 176.3K | 13.1K | 3.16M | 79.30% | ↗ |
| 26 | 2020 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 675.0K | — | — | 6.55M | 506.3K | 83.3K | 7.82M | 83.82% | ↗ |
| 27 | 2020 | Rafael Amado, M.D. Chief Medical Officer and Executive Vice President of Research and Development | 510.0K | 75.0K | 561.2K | 1.26M | 255.0K | — | 2.66M | 68.47% | ↗ |
| 28 | 2020 | Alison Moore, Ph.D. Chief Technical Officer | 440.0K | — | 561.2K | 1.26M | 220.0K | — | 2.48M | 73.43% | ↗ |
| 29 | 2020 | Eric Schmidt, Ph.D. Chief Financial Officer | 440.0K | — | 561.2K | 1.26M | 220.0K | — | 2.48M | 73.43% | ↗ |
| 30 | 2020 | Veer Bhavnagri General Counsel | 425.0K | — | 537.5K | 1.21M | 212.5K | 9.4K | 2.40M | 73.01% | ↗ |
| 31 | 2020 | Veer Bhavnagri General Counsel | 425.0K | — | 537.5K | 1.21M | 212.5K | 9.4K | 2.40M | 73.01% | ↗ |
| 32 | 2019 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 600.0K | — | 4.65M | — | 363.0K | 250.0K | 11.19M | 41.56% | ↗ |
| 33 | 2019 | Rafael Amado, M.D. Chief Medical Officer and Executive Vice President of Research and Development | 145.8K | — | 4.25M | 2.76M | 71.7K | 225.0K | 7.45M | 94.06% | ↗ |
| 34 | 2019 | Rafael Amado, M.D. Chief Medical Officer and Executive Vice President of Research and Development | 145.8K | — | 4.25M | — | 71.7K | 225.0K | 7.45M | 57.03% | ↗ |
| 35 | 2019 | Eric Schmidt, Ph.D. Chief Financial Officer | 425.0K | — | 1.33M | — | 187.0K | — | 3.46M | 38.39% | ↗ |
| 36 | 2019 | Alison Moore, Ph.D. Chief Technical Officer | 425.0K | — | 996.3K | — | 187.0K | — | 3.13M | 31.85% | ↗ |
| 37 | 2018 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 362.4K | — | 8.95M | — | 217.6K | 250.0K | 12.85M | 69.64% | ↗ |
| 38 | 2018 | David Chang, M.D., Ph.D. President and Chief Executive Officer | 362.4K | — | 8.95M | 3.07M | 217.6K | 250.0K | 12.85M | 93.54% | ↗ |
| 39 | 2018 | Joshua Kazam Former President | — | — | 3.59M | — | — | — | 3.59M | 100.00% | ↗ |
| 40 | 2018 | Eric Schmidt, Ph.D. Chief Financial Officer | 201.2K | — | — | — | 88.1K | — | 2.59M | 0.00% | ↗ |
| 41 | 2018 | Eric Schmidt, Ph.D. Chief Financial Officer | 201.2K | — | — | 2.30M | 88.1K | — | 2.59M | 88.82% | ↗ |
| 42 | 2018 | Alison Moore, Ph.D. Chief Technical Officer | 233.3K | — | — | — | 102.1K | 100.0K | 1.84M | 0.00% | ↗ |
| 43 | 2018 | Alison Moore, Ph.D. Chief Technical Officer | 233.3K | — | — | 1.40M | 102.1K | 100.0K | 1.84M | 76.29% | ↗ |
| 44 | 2017 | Joshua Kazam Former President | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David D. Chang | Co-Founder, President, Chief Executive Officer & Director | 1M | — |
| Zachary J. Roberts | Executive Vice President of Research & Development and Chief Medical Officer | 750.8K | — |
| Arie S. Belldegrun | Co-Founder & Executive Chairman | 728.7K | — |
| Geoffrey Parker | Executive Vice President & Chief Financial Officer | 707.0K | male |
| Joshua A. Kazam | Co-Founder & Director | 47.0K | male |
| Earl Douglas | Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary | — | male |
| Benjamin Beneski | Senior Vice President & Chief Technical Officer | — | male |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer | — | female |
| Annie Yoshiyama | SVP & Corporate Controller | — | female |
| Susan R. Lundeen | Chief People Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALLO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
